期刊文献+

心力衰竭患者血清NT-proBNP和sST2水平变化及临床意义 被引量:33

Clinical significance of serum NT-proBNP and soluble ST2 changes in patients with heart failure
下载PDF
导出
摘要 目的探讨N末端B型脑钠肽前体(NT-proBNP)和可溶性ST2(sST2)在心力衰竭(简称心衰)患者血清中的水平变化及临床意义。方法分析202例慢性心衰住院患者血清NT-proBNP、sST2水平,采用纽约心脏病学会(NYHA)标准和超声心动图检查判定患者心功能。分析比较2种生物学标志物水平在不同心功能分级患者的差异,并分析二者与NYHA心功能分级的相关性。结果两组患者血清NT-proBNP和sST2水平比较,差异均有统计学意义(P=0.001、0.002),且随NYHA分级的增加,血清NT-proBNP和sST2水平均逐渐升高。低危组患者吸烟史、左室射血分数(LVEF)、肾小球滤过率估计值(eGFR)与高危组比较,差异有统计学意义(P<0.05)。血清NT-proBNP与sST2水平成呈正相关(r=0.247,P=0.013);sST2与NYHA分级呈正相关(r=0.412,P=0.001),与LVEF呈负相关(r=-0.167,P=0.049)。NT-proBNP与NYHA分级呈正相关(r=0.536,P=0.001),与LVEF、eGFR呈负相关(r=-0.317、-0.385,P=0.001)。NT-proBNP和sST2检测评估心衰患者心功能分级的受试者工作特征曲线(ROC)的曲线下面积(AUC)分别为0.824和0.701,与NT-proBNP相比,sST2在评估慢性心衰患者心功能分级方面无明显优势,二者联合检测评估心衰患者心功能分级的AUC达0.872,灵敏度和特异度分别达76.1%和93.3%。结论血清sST2水平与NT-proBNP呈正相关,与NT-proBNP比较,sST2受肾功能影响较小,sST2联合NT-proBNP检测有助于提高心衰患者心功能分级评估,是对NT-proBNP的良好补充。 Objective To investigate N-terminal B-type natriuretic peptide and soluble suppression of tumorigenicity(sST2)levels in inpatients with chronic heart failure.Methods The serum concentrations of NT-proBNP and sST2 in 202 hospitalized patients with chronic heart failure were analyzed.The correlation between the two biomarkers and NYHA functional classifications was analyzed and the differences in the two biomarkers between the two groups were analyzed.Results The levels of NT-proBNP(P<0.001)and sST2(P=0.002)were significantly different between the two groups.The levels of NT-proBNP and sST2 gradually increased with the increase of NYHA classification.Low-risk group and high-risk group also showed statistically significant differences in smoking history,LVEF,eGFR.Spearman correlation analysis showed that there was a positive correlation between NT-proBNP and sST2 level(r=0.247,P<0.013).Spearman correlation analysis showed that sST2 was positively correlated with NYHA,and correlated negatively with LVEF.NT-proBNP was positively correlated with NYHA classification,negatively correlated with LVEF and eGFR.ROC curve analys showed that the area under the curve(AUC)of low-risk group and high-risk group with NT-proBNP and sST2 were 0.824 and 0.701,respectively.Compared with NT-proBNP,sST2 had no obvious advantage in the assessment of cardiac function in patients with chronic heart failure.The combined AUC area of the two biomarkers was 0.872,with a sensitivity and specificity of 0.761 and 0.933 respectively.Conclusion sST2 levels were positively correlated with NT-proBNP and sST2 is superior to NT-proBNP in the diagnosis of patients with heart failure who have renal dysfunction simutaneously,sST2 combined with NT-proBNP was helpful in improving heart function grading assessment in patients with heart failure.which was a good supplement of NT-proBNP.
作者 杜坤 张梦情 邓琳 张广慧 DU Kun;ZHANG Mengqing;DENG Lin;ZHANG Guanghui(Department of Laboratory Medicine,Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China)
出处 《国际检验医学杂志》 CAS 2019年第1期43-47,共5页 International Journal of Laboratory Medicine
关键词 心力衰竭 慢性病 实验室技术和方法 N末端B型脑钠肽前体 可溶性ST2 heart failure chronic disease laboratory techniques and procedures N-terminal B-type brain natriuretic peptide precursor soluble suppression of tumorigenicity
  • 相关文献

参考文献2

二级参考文献37

  • 1周京敏.心力衰竭生化标志物[EB/OL].东方心脏病会议.[2010-05-28].http://www.occmd.org/view_detail.aspx?id=2678.
  • 2Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association[ J]. Circulation, 2012, 125( 1 ) : e2-e220.
  • 3Daniels LB, Maisel AS. Natriuretic peptides [ JJ. J Am Coll Cardiol, 2007, 50(25), 2357-2368.
  • 4Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echzcardiographic substudy [J]. Eur Heart J, 2006, 27(7) : 839-845.
  • 5Januzzi JL Jr, Rehman S, Mueller T, et al. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients[J]. Clin Chem, 2010, 56(12) : 1814-1821.
  • 6van Kimmenade RR, Januzzi JL Jr. Emerging biomarkers in heart failure[J]. Clin Chem, 2012, 58(1): 127-138.
  • 7Wang, YC, Yu CC, Chiu FC, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients[J]. J Card Fail, 2013, 19(3) : 163-168.
  • 8Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction [ J 1. Circulation, 2002, 106(23) : 2961-2966.
  • 9lwahana H, anagisawa K, ho-Kosaka A, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptorrelated human ST2 gene in UT-7 and TM12 cells[J]. Eur J Biochem, 1999, 264(2): 397-406.
  • 10Barksby HE, Lea SR, Preshaw PM, et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders [ J ]. Clin Exp Immunol, 2007, 149 ( 2 ) : 217-225.

共引文献4691

同被引文献311

引证文献33

二级引证文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部